Ratings by JPMorgan (Priyanka Grover)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/30/2026 | Recursion Pharmaceuticals | RXRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2026 | Mereo BipPharma Group | MREO | Downgrade | Neutral (Overweight) |
0.36 (0.32) |
-11.11% | Details | |
| 12/17/2025 | Recursion Pharmaceuticals | RXRX | Upgrade | Overweight (Neutral) |
4.20 (3.16) |
-24.76% | Details | |
| 8/25/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2025 | Mereo BipPharma Group | MREO | New Coverage | Overweight (N/A) |
2.35 (0.36) |
-84.68% | Details |
